Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The PUB Study: Somatostatin in Acute Severe UGIB
NCT00152399Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2000
- Primary completion
- Oct 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in upper gastrointestinal bleeding (UGIB) and Peptic ulcer hemorrhage (PUB) comparing Somatostatin with Placebo (2 arms). Primary endpoint: Failure rate at 72 hours. Started Sep 2000; status: completed.
02
Drugs
somatostatin
03
Conditions
upper gastrointestinal bleeding (UGIB)Peptic ulcer hemorrhage (PUB)
Beyond the preview
Go deeper on NCT00152399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152399.